Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients

(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated a survival benefit for patients with first recurrence of a glioblastoma when treated with the multikinase inhibitor regorafenib (REG) instead of lomustine. The aim of this retrospective study was to investigate...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Main Authors: Zeiner, Pia S., Kinzig, Martina, Divé, Iris, Maurer, Gabriele D., Filipski, Katharina, Harter, Patrick N., Senft, Christian, Bähr, Oliver, Hattingen, Elke, Steinbach, Joachim P., Sörgel, Fritz, Voss, Martin, Steidl, Eike, Ronellenfitsch, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947028/
https://ncbi.nlm.nih.gov/pubmed/31766326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8122031
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares